Figure 1 shows a schematic diagram of quantitative phosphoproteomic analysis of gastric tumor tissues (Ts) and non-tumor adjacent tissues (NATs) before and after trastuzumab-based treatment of four patients with HER2-positive cancer and Ts and NATs from four patients with HER2-negative cancer (Fig. S1a). This evidence concerns the gene ERBB2 and neoplasm.